<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03662828</url>
  </required_header>
  <id_info>
    <org_study_id>KAPOSI-1</org_study_id>
    <nct_id>NCT03662828</nct_id>
  </id_info>
  <brief_title>Epidemiological Description of the Kaposi's Disease in France's Southeast</brief_title>
  <acronym>KAPOSI-1</acronym>
  <official_title>Epidemiological Description of the Kaposi's Disease in France's Southeast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Direction Centrale du Service de Santé des Armées</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Direction Centrale du Service de Santé des Armées</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the prevalence of the Kaposi's disease in France's
      southeast on 10 years (from 2007 to 2017)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kaposi's disease is a multifocal disease with cutaneous expression in more than 95% of cases.

      There are 4 forms : Mediterranean, Endemic (Sub-Saharan Africa), iatrogenic and epidemic
      (HIV) The physiological hypotheses to explain the disease are not clear. A proliferation of
      immunity cells in blood vessels and also an undetermined role of the human herpes virus 8
      (HHV-8) could be involved.

      The treatment is complex and not standardized. There are a lot of different treatments.

      The purpose of this study is to evaluate the prevalence and described the characteristics and
      the treatment of the Kaposi's disease in the France's southeast on 10 years, from 2007 to
      2017.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Kaposi's disease</measure>
    <time_frame>10 years (2007-2017)</time_frame>
    <description>Diagnosed patients with biopsy, in France's southeast</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Descriptive analysis of the different form of the Kaposi's disease in the population</measure>
    <time_frame>10 years (2007-2017)</time_frame>
    <description>Mediterranean form, endemic form, iatrogenic form and epidemic form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive analysis of the population : sociodemographic</measure>
    <time_frame>10 years (2007-2017)</time_frame>
    <description>sociodemographic characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive analysis of the population : paraclinical</measure>
    <time_frame>10 years (2007-2017)</time_frame>
    <description>paraclinical characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive analysis of the population : clinical</measure>
    <time_frame>10 years (2007-2017)</time_frame>
    <description>clinical characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive analysis of the population : therapeutic</measure>
    <time_frame>10 years (2007-2017)</time_frame>
    <description>therapeutic care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival analysis</measure>
    <time_frame>10 years (2007-2017)</time_frame>
    <description>mortality rate</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Kaposi's Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Diagnosed patients with a Kaposi's disease by biopsy from January 2007 to December 2017
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed patients with a Kaposi's disease by biopsy from January 2007 to December
             2017

        Exclusion Criteria:

          -  Opposition to the use of personal data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIA Laveran</name>
      <address>
        <city>Marseille</city>
        <state>Bouche Du Rhone</state>
        <zip>13384</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI de Fréjus</name>
      <address>
        <city>Fréjus</city>
        <state>Var</state>
        <zip>83600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Sainte-Anne</name>
      <address>
        <city>Toulon</city>
        <state>Var</state>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>July 23, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kaposi's disease</keyword>
  <keyword>HHV8</keyword>
  <keyword>Prevalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Xeroderma Pigmentosum</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

